Literature DB >> 32264803

CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.

Fatima Akram1, Zeeshan Ahmed1, Hamza Khan1, Muhammad Shrafat Ali1.   

Abstract

Cancer is one of the most leading causes of mortality all over the world and remains a foremost social and economic burden. Mutations in the genome of individuals are taking place more frequently due to the excessive progress of xenobiotics and industrialization in the present world. With the progress in the field of molecular biology, it is possible to alter the genome and to observe the functional changes derived from genetic modulation using gene-editing technologies. Several therapies have been applied for the treatment of malignancy which affect the normal body cells; however, more effort is required to develop vsome latest therapeutic approaches for cancer biology and oncology exploiting these molecular biology advances. Recently, the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated protein 9 (Cas9) system has emerged as a powerful technology for cancer therapy because of its great accuracy and efficiency. Genome editing technologies have demonstrated a plethora of benefits to the biological sciences. CRISPR- Cas9, a versatile gene editing tool, has become a robust strategy for making alterations to the genome of organisms and a potent weapon in the arsenal of tumor treatment. It has revealed an excellent clinical potential for cancer therapy by discovering novel targets and has provided the researchers with the perception about how tumors respond to drug therapy. Stern efforts are in progress to enhance its efficiency of sequence specific targeting and consequently repressing offtarget effects. CRISPR-Cas9 uses specific proteins to convalesce mutations at genetic level. In CRISPR-Cas9 system, RNA-guided Cas9 endonuclease harnesses gene mutation, DNA deletion or insertion, transcriptional activation or repression, multiplex targeting only by manipulating 20-nucleotide components of RNA. Originally, CRISPR-Cas9 system was used by bacteria for their defense against different bacteriophages, and recently this system is receiving noteworthy appreciation due to its emerging role in the treatment of genetic disorders and carcinogenesis. CRISPR-Cas9 can be employed to promptly engineer oncolytic viruses and immune cells for cancer therapeutic applications. More notably, it has the ability to precisely edit genes not only in model organisms but also in human being that permits its use in therapeutic analysis. It also plays a significant role in the development of complete genomic libraries for cancer patients. In this review, we have highlighted the involvement of CRISPR-Cas9 system in cancer therapy accompanied by its prospective applications in various types of malignancy and cancer biology. In addition, some other conspicuous functions of this unique system have also been discussed beyond genome editing. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  CRISPR; genome editing; malignancy; mutations; therapeutic tool; therapy

Mesh:

Year:  2020        PMID: 32264803     DOI: 10.2174/0929866527666200407112432

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  7 in total

Review 1.  Drug delivery approaches for HuR-targeted therapy for lung cancer.

Authors:  Rajeswari Raguraman; Santny Shanmugarama; Meghna Mehta; Jo Elle Peterson; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-11-22       Impact factor: 15.470

2.  CRISPR/Cas9-mediated knockout of HO-1 decreased the proliferation and migration of T47D cells and increased cisplatin-induced apoptosis: an in vitro study.

Authors:  Sahar Evazi Bakhshi; Amaneh Mohammadi Roushandeh; Mehryar Habibi Roudkenar; Shima Shekarchi; Mohammad Hadi Bahadori
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

Review 3.  Coronary artery disease and cancer: a significant resemblance.

Authors:  Sudeshna Rakshit; Geetha Shanmugam; Koustav Sarkar
Journal:  Med Oncol       Date:  2022-09-07       Impact factor: 3.738

Review 4.  CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics.

Authors:  Prashant Kumar; Yashpal Singh Malik; Balasubramanian Ganesh; Somnath Rahangdale; Sharad Saurabh; Senthilkumar Natesan; Ashish Srivastava; Khan Sharun; Mohd Iqbal Yatoo; Ruchi Tiwari; Raj Kumar Singh; Kuldeep Dhama
Journal:  Front Cell Infect Microbiol       Date:  2020-11-02       Impact factor: 5.293

Review 5.  Targeting Epigenetic Modifications in Uveal Melanoma.

Authors:  Pooneh Chokhachi Baradaran; Zuzana Kozovska; Alena Furdova; Bozena Smolkova
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

Review 6.  An Insight into Modern Targeted Genome-Editing Technologies with a Special Focus on CRISPR/Cas9 and its Applications.

Authors:  Fatima Akram; Sania Sahreen; Farheen Aamir; Ikram Ul Haq; Kausar Malik; Memoona Imtiaz; Waqas Naseem; Narmeen Nasir; Hafiza Mariam Waheed
Journal:  Mol Biotechnol       Date:  2022-04-26       Impact factor: 2.860

Review 7.  Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.

Authors:  Dito Anurogo; Nova Yuli Prasetyo Budi; Mai-Huong Thi Ngo; Yen-Hua Huang; Jeanne Adiwinata Pawitan
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.